XML 39 R30.htm IDEA: XBRL DOCUMENT
v3.21.1

Stock-Based Compensation (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
Summary of Stock-based Compensation Expense | Oncocyte recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the three months ended March 31, 2021 and 2020 (unaudited and in thousands):
|  | Three Months Ended March 31, |
|  | 2021 |  |  | 2020 |
Cost of revenues |  | $ | 22 |  |  | $ | 5 |
Research and development |  |  | 257 |  |  |  | 194 |
General and administrative |  |  | 778 |  |  |  | 634 |
Sales and marketing |  |  | 233 |  |  |  | 104 |
Total stock-based compensation expense |  | $ | 1,290 |  |  | $ | 937 |
Schedule of Assumptions Used to Calculate Fair Value of Stock Options | The assumptions that were used to calculate the grant date fair value of Oncocyte’s employee and non-employee stock option grants for the three months ended March 31, 2021 and 2020 were as follows (unaudited):
|  | Three Months Ended March 31, |
|  | 2021 |  |  | 2020 |
Expected life (in years) |  |  | 6.0 |  |  |  | 6.0 |
Risk-free interest rates |  |  | 1.02% |  |  |  | 1.34% |
Volatility |  |  | 102.62% |  |  |  | 105.09% |
Dividend yield |  |  | -% |  |  |  | -% |
2010 Plan Activity [Member] |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
Summary of Stock Option Activity | A summary of Oncocyte’s 2010 Plan activity and related information follows (in thousands except weighted average exercise price):
Options |  | Shares Available for Grant |  |  | Number of Options Outstanding |  |  | Weighted Average Exercise Price |
Balance at December 31, 2020 |  |  | - |  |  |  | 1,218 |  |  | $ | 3.55 |
Options exercised |  |  | - |  |  |  | (90) |  |  | $ | 2.09 |
Options forfeited, canceled and expired |  |  | - |  |  |  | - |  |  | $ | - |
Balance at March 31, 2021 |  |  | - |  |  |  | 1,128 |  |  | $ | 3.65 |
Exercisable at March 31, 2021 |  |  |  |  |  |  | 1,081 |  |  | $ | 3.76 |
2018 Incentive Plan Activity [Member] |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] |
Summary of Stock Option Activity | A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise price):
|  | Shares Available for Grant |  |  | Number of Options Outstanding |  |  | Number of RSUs Outstanding |  |  | Weighted Average Exercise Price |
Balance at December 31, 2020 |  |  | 3,346 |  |  |  | 7,212 |  |  |  | 201 |  |  | $ | 2.60 |
RSUs vested |  |  | - |  |  |  | - |  |  |  | - |  |  | $ | - |
RSUs granted |  |  | - |  |  |  | - |  |  |  | - |  |  | $ | - |
Options granted |  |  | (2,966) |  |  |  | 2,966 |  |  |  | - |  |  | $ | 5.12 |
Options exercised |  |  | - |  |  |  | (195) |  |  |  | - |  |  | $ |  |
Options forfeited/cancelled |  |  | 76 |  |  |  | (76) |  |  |  | - |  |  | $ | 2.69 |
Balance at March 31, 2021 |  |  | 456 |  |  |  | 9,907 |  |  |  | 201 |  |  | $ | 3.35 |
Options exercisable at March 31, 2021 |  |  |  |  |  |  | 2,849 |  |  |  |  |  |  | $ | 2.67 |

X
- Definition Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -URI http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 + Details
Name: | us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_PlanNameAxis=OCX_TwoThousandTenPlanActivityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=OCX_TwoThousandEighteenPalnActivityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |